Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
2 hedge funds and large institutions have $425K invested in Osiris Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
32% less capital invested
Capital invested by funds: $621K → $425K (-$196K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$19K |
| 2 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIM
1
Freedom Investment Management
Hartford,
Connecticut
| $370K | -$19K | -4,138 | -5% |
|
2
Public Employees Retirement Association of Colorado
Denver,
Colorado
| $55K | – | – | – |
|
|
MAM
3
Meeder Asset Management
Dublin,
Ohio
| – | -$3K | -398 | Closed |
|
OSIR Hedge Fund Activity: Q3 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q3 2017, worth a combined $425K — down 32% from $621K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of OSIR and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Freedom Investment Management, cutting an estimated $19K.
- 2 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q3 2017, down from 3 in Q2 2017.
- Funds reported $425K of Osiris Therapeutics, Inc. Common Stock stock for Q3 2017, down 32% quarter-over-quarter.
- 0 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q3 2017 and 1 closed out, a net change of -1 holder.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q3 2017 was Freedom Investment Management, an estimated $19K sold.
Based on aggregated 13F filings for Q3 2017.